WallStreetZenWallStreetZen

NASDAQ: ELVN
Enliven Therapeutics Inc Stock Ownership - Who owns Enliven Therapeutics?

OverviewForecastEarningsDividendOwnership

Insider buying vs selling

Have Enliven Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Richard A. HeymanDirector2024-04-1580$20.68
$1.65kSell
Richard A. HeymanDirector2024-04-151,190$19.94
$23.73kSell
Richard A. HeymanDirector2024-04-11649$25.00
$16.23kSell
Anish PatelCHIEF OPERATING OFFICER2024-04-1114,903$2.48
$36.96kBuy
Richard A. HeymanDirector2024-04-115,045$25.03
$126.28kSell
Rahul D. BallalDirector2024-04-113,068$25.21
$77.34kSell
Rahul D. BallalDirector2024-04-1120,032$25.00
$500.70kSell
Rahul D. BallalDirector2024-04-1130,300$23.14
$701.02kSell
Rahul D. BallalDirector2024-04-114,580$19.68
$90.13kBuy
Rahul D. BallalDirector2024-04-1148,820$12.60
$615.13kBuy

1 of 13

ELVN insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ELVN insiders and whales buy or sell their stock.

ELVN Shareholders

What type of owners hold Enliven Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Orbimed Advisors LLC21.76%8,998,338$150.99MInstitution
David P. Bonita20.31%8,398,136$140.92MInsider
5am Partners Vi LLC19.69%8,142,154$136.63MInsider
Fmr LLC12.48%5,161,242$86.61MInstitution
5am Venture Management LLC12.48%5,160,975$86.60MInstitution
Ra Capital Management LP8.65%3,576,813$60.02MInsider
Vr Adviser LLC7.15%2,954,902$49.58MInstitution
Commodore Capital LP7.02%2,901,816$48.69MInstitution
Orbimed Advisors LLC6.82%2,820,516$47.33MInsider
New Enterprise Associates 14 LP6.31%2,611,050$43.81MInsider

1 of 3

ELVN vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ELVN46.22%53.78%Net SellingNet Selling
LBPH45.89%0.09%Net Selling
AUPH36.80%3.18%Net SellingNet Selling
PLRX70.74%29.26%Net Selling
ARCT87.10%12.90%Net SellingNet Selling
View Top Biotech Stocks

Enliven Therapeutics Stock Ownership FAQ

Who owns Enliven Therapeutics?

Enliven Therapeutics (NASDAQ: ELVN) is owned by 94.32% institutional shareholders, 109.75% Enliven Therapeutics insiders, and 0.00% retail investors. David P. Bonita is the largest individual Enliven Therapeutics shareholder, owning 8.40M shares representing 20.31% of the company. David P. Bonita's Enliven Therapeutics shares are currently valued at $144.28M.

If you're new to stock investing, here's how to buy Enliven Therapeutics stock.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.